Evidence map›Paper›PMID 17114791›Full record

ArticleThe Journal of biological chemistry2007

Identification of the hydrophobic ligand binding pocket of the S1P1 receptor.

Yuko Fujiwara, Daniel A Osborne, Michelle D Walker, De-an Wang, Debra A Bautista, Karoly Liliom, James R Van Brocklyn, Abby L Parrill, Gabor Tigyi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2009
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Yuko FujiwaraDepartment of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
Daniel A Osborne
Michelle D Walker
De-an Wang
Debra A Bautista
Karoly Liliom
James R Van Brocklyn
Abby L Parrill
Gabor Tigyi
University of Tennessee Health Science Center · USUniversity of Memphis · USEastern Kentucky University · USInstitute of Molecular Life Sciences · HUThe Ohio State University · US

Funding

Ligand Recognition by Phospholipid Growth Factor ReceptorsR01CA092160 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2001 to 2022
$5.9M
THERAPEUTICALLY PROMISING PHOSPHOLIPID GROWTH FACTORSR01HL061469 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 1999 to 2006
$2.0M
NCI NIH HHS CA92160NCI NIH HHS R01 CA092160NHLBI NIH HHS HL61469NHLBI NIH HHS R01 HL061469
6 · The paper itself

Abstract

Sphingosine 1-phosphate (S1P), a naturally occurring sphingolipid mediator and also a second messenger with growth factor-like actions in almost every cell type, is an endogenous ligand of five G protein-coupled receptors (GPCRs) in the endothelial differentiation gene family. The lack of GPCR crystal structures sets serious limitations to rational drug design and in silico searches for subtype-selective ligands. Here we report on the experimental validation of a computational model of the ligand binding pocket of the S1P1 GPCR surrounding the aliphatic portion of S1P. The extensive mutagenesis-based validation confirmed 18 residues lining the hydrophobic ligand binding pocket, which, combined with the previously validated three head group-interacting residues, now complete the mapping of the S1P ligand recognition site. We identified six mutants (L3.43G/L3.44G, L3.43E/L3.44E, L5.52A, F5.48G, V6.40L, and F6.44G) that maintained wild type [32P]S1P binding with abolished ligand-dependent activation by S1P. These data suggest a role for these amino acids in the conformational transition of S1P1 to its activated state. Three aromatic mutations (F5.48Y, F6.44G, and W6.48A) result in differential activation, by S1P or SEW2871, indicating that structural differences between the two agonists can partially compensate for differences in the amino acid side chain. The now validated ligand binding pocket provided us with a pharmacophore model, which was used for in silico screening of the NCI, National Institutes of Health, Developmental Therapeutics chemical library, leading to the identification of two novel nonlipid agonists of S1P1.

Indexed as

Models, MolecularBinding SitesComputational BiologyHumansLigandsLysophospholipidsMolecular StructureProtein BindingReceptors, G-Protein-CoupledReceptors, LysosphingolipidSphingosineStructure-Activity RelationshipLigandsLysophospholipidsReceptors, G-Protein-CoupledReceptors, LysosphingolipidSphingosinesphingosine 1-phosphate

Identifiers

PMID17114791
PMCPMC3446783
OpenAlexW2023277555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.